Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the feasibility of pazopanib treatment
interruption with reintroduction at progression in iodine refractory progressive
Differentiated Thyroid Cancer (DTC) patients as compared to pazopanib continuous
administration.